November 13-15, 2018

Boston, MA, USA

Twitter logo for website footers 2


Apellis - EPC March 15

Apellis’ approach is centered on the inhibition of the complement system, which is a cascade of interacting proteins and is an integral component of the immune system. We have developed our lead product candidates, which are analogs of the cyclic peptide compstatin, based on technology that we have exclusively licensed from the Trustees of the University of Pennsylvania. Our lead compounds are designed to broadly inhibit complement C3, the central protein in the complement cascade. Under conditions of excessive or uncontrolled activation, the complement system plays a key role in a wide range of autoimmune and inflammatory diseases..